Your search for bevacizumab returned 4 results

The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.

The approval was based on data from the SORAYA trial.

Alymsys is a vascular endothelial growth factor inhibitor.

Vegzelma is a vascular endothelial growth factor inhibitor.